The relation of rheumatic diseases and their treatment to clinical renal involvement
Authors:
A. Klíčová 1; P. Horák 1; T. Tichý 2; J. Zadražil 1
Authors‘ workplace:
III. interní klinika – nefrologická, revmatologická a endokrinologická FN a LF UP, Olomouc
1; Ústav klinické a molekulární patologie FN a LF UP, Olomouc
2
Published in:
Čes. Revmatol., 23, 2015, No. 4, p. 133-145.
Category:
Review Article
Overview
Number of rheumatic diseases manifest with involvement of renal and urinary system. Connective tissue diseases and vasculitides are often accompanied by glomerulonephritis. Involvement of renal interstitium is often present in connective tissue diseases such as certain forms of systemic lupus or Sjögren's syndrome, and vascular involvement typical for systemic sclerosis or antiphospholipid syndrome. Inflammatory diseases may also be accompanied by AA amyloidosis associated with nephrotic syndrome and renal failure. Renal impairment occurs frequently in patients with hyperuricaemia. The effect of drugs used for treatment of rheumatic diseases on a kidney represents a separate chapter. On the other hand, even patients on dialysis often need to continue the treatment of rheumatic diseases. These questions are explored in the present review article.
Key words:
rheumatic diseases, renal involvement, hemodialysis, complications, specific isssues of the treatment
Sources
1. Bomback A, Appel G. End-stage renal disease due to lupus nephritis. Uptodate 2014; updated 8.8.2013.
2. Weening JJ, D´Agati, WD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241–250.
3. Naiker I P, Chrystal V, Randeree I G, et al. The significance of arterial hypertension at the onset of clinical lupus nephritis. Postgrad Med J 1997; 73: 230–233.
4. Contreras G, Roth D, Pardo V, Strikre LG, et al. Lupus nephritis: A clinical review for practicing nephrologists. Clin Nephrol 2002; 57: 95–107.
5. Joseph RE, Radhakrishnan J, Appel GB. Antiphospholipid antibody syndrome and renal disease. Curr Opin Nephrol Hypertens 2001; 10: 175–181.
6. Adu D, Emery P, Madaio M. Rheumatology and the kidney. Oxford University Press, 2nd Edition 2012, 488.
7. Schwartz MM, Kawala KS, Corwin HL, Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int 1987; 32(2): 274.
8. Ponticelli C, Moroni G. Renal transplantation in lupus nephritis. Lupus 2005; 14(1): 95.
9. O'Callaghan CA. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract Res Clin Rheumatol 2004; 18: 411–427.
10. Denton CP, Lapadula G, Mouthon L, Müller-Lander U. Renal complication and scleroderma renal crisis. Rheumatology (Oxford) 2009; 48: 32–35.
11. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485–494.
12. Varga J, Fenves A. Renal disease in systemic sclerosis (scleroderma), including scleroderma renal crisis. Uptodate 2014; updated 13.2. 2014.
13. Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 1994; 8: 627–634.
14. Rose BD. Renal manifestations of systemic vasculitis. Uptodate 2012; updated 6.6.2011.
15. Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study 2008; 47: 350-354.
16. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400–1406.
17. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666–675.
18. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2: 218–239.
19. Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore) 1960; 39: 405.
20. Moe OW. Posing the question again: does chronic uric acid nephropathy exist? J Am Soc Nephrol 2010; 21(3): 395–397.
21. Hartus E, Budd R, Firestein G, et al. Kelley‘s Textbook of Rheumatology 2004; 7: 1402–1425.
22. Garella S, Matarese R A. Renal effects of prostaglandins and clinical adverse gement: the MATRIX study. Rheumatology (Oxford) 2008; 47: 350–354.
23. Gansevoort R T, Heeg J E, Vriesenorp R, et al. Antiproteinuric drugs in patients with idiopathic membranosus glomerulopathy. Nephrol Dial Transplant 1992; 91–96.
24. Akhund L, Quinet R J, Ishag S. Celecoxib-related renal papillary necrosis. Arch Intern Med 2003; 163: 114–115.
25. Jankovic S, Aleksic J, Rakovic S, et al. Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleedingamong patients on hemodialysis. J Nephrol 2009; 22: 502–507.
26. Hall C L. The natural course of gold and penicillamine nephropathy: a long term study of 54 patients. Adv Exp Med Biol 1989; 252: 274–356.
27. Bennet W M, DeMattos A, Meyers M M, Andoh T Barry J M. Chronic cyclosporin nephrotoxicity. The Achille´s heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089–1100.
28. http://www.sukl.cz/download/spc/SPC23090.pdf
29. Saland J M, Leafly P J, Hansch E. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002; 17: 825–829.
30. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000235/WC500026289.pdf
31. Maršálková P, Grundmann M. Farmakokinetika a klinické aplikace vybraných imunosupresiv. Klin Farmakol Farm 2009; 23(3): 138–141.
32. Swarup A, Sachdeva N, Schumacher R. Dosing of Antirheumatic Drug in Renal Disease and Dialysis. J Clin Rheum 2004; 10: 190–204.
33. Perez R P, Calabozo M, Pijaan JI, et al. Effect of urate-lowering therapy on the velocity of size of reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356–360.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2015 Issue 4
Most read in this issue
- The relation of rheumatic diseases and their treatment to clinical renal involvement
- Serum biomarkers in axial spondyloarthritis
- Deformation analysis of the right ventricle using speckle tracking in the diagnosis of pulmonary arterial hypertension in patients with systemic sclerosis and mixed connective tissue disease